Tigecycline-Associated Coagulopathy: A Single-Center Retrospective Analysis

Wang D.a· Lin C.a· Gu C.b· Wu Y.a· Wang S.a

Author affiliations

aDepartment of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
bDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: January 29, 2022
Accepted: May 30, 2022
Published online: July 12, 2022

Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 5

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

Introduction: The purpose of this study was to assess clinical characteristics and risk factors for tigecycline-associated prothrombin time (PT) and activated partial thromboplastin time (aPTT) prolongation. Methods: We performed a retrospective analysis on coagulation parameters before and during tigecycline treatment in 55 patients in our hospital with severe infections, mainly pneumonia caused by Acinetobacter baumannii. Patients were divided into different groups according to prolongation of PT and aPTT, and clinical features involved were explored. Univariate and multivariable binary logistic regression analyses were used to identify risk factors for tigecycline-associated PT and aPTT increase. Results: We found that PT values increased from 12.73 ± 1.87 to 13.86 ± 2.06 during the treatment compared with premedication (p < 0.001), and the aPTT level prolonged significantly from 33.63 ± 11.24 to 38.15 ± 11.81 (p < 0.001). The multivariate analyses identified 2 variables that were associated with tigecycline-induced PT prolongation: albumin level (p = 0.018) and weight-adjusted tigecycline dosage (p = 0.005). In addition, treatment duration was the only risk factor for tigecycline-induced aPTT prolongation (p = 0.043). Conclusion: Albumin level, weight-adjusted tigecycline dosage, treatment duration may serve as risk indicators for tigecycline-associated coagulation dysfunction. Physicians should be careful with coagulation disorder when prescribing tigecycline in clinical practice, especially in patients with risk factors.

© 2022 S. Karger AG, Basel

References Marco F, Dowzicky MJ. Antimicrobial susceptibility among important pathogens collected as part of the tigecycline evaluation and surveillance trial (T.E.S.T.) in Spain, 2004–2014. J Glob Antimicrob Resist. 2016 Sep;6:50–6. Kadoyama K, Sakaeda T, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull. 2012;35(6):967–70. Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019 Dec;41(6):1408–13. Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010 Oct;89(10):1063–4. Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):681–4. Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Vasileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis. 2015;47(10):743–6. McMahan J, Moenster RP. Tigecycline-induced coagulopathy. Am J Health Syst Pharm. 2017 Feb 1;74(3):130–4. Wu X, Zhao P, Dong L, Zhang X. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine. 2017 Dec;96(49):e9124. Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56–7. Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325–32. Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015 Jan;45(1):90–3. Hakeam HA, Al Duhailib Z, Salahuddin N, Amin T. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study. J Chemother. 2018 Jul;30(4):224–32. Akdağ D, Işıkgöz-Taşbakan M, Pullukcu H, Sipahi H, Sipahi OR. Tigecycline versus INR increase; more than expected? Expert Opin Drug Saf. 2020 Mar;19(3):335–7. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005 Sep;9(5):251–61. Brandtner A, Bachler M, Fries D, Hermann M, Ruehlicke J, Fux V, et al. Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system. Antibiotics. 2020 Feb 14;9(2):84. Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015 Mar;59(3):1650–5. Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine. 2018 Sep;97(38):e12467. Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P, Rivera-Sánchez L, Espinosa-Pereiro J, Mestre-Torres J, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm. 2020 Aug;42(4):1184–9. Hu J, Xiao YH, Zheng Y, Lai YX, Fang XL, Fang Q. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol. 2020 Jul;76(7):913–22. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005 Jul;52(3):165–71. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333–40. Leng B, Xue YC, Zhang W, Gao TT, Yan GQ, Tang H. A retrospective analysis of the effect of tigecycline on coagulation function. Chem Pharm Bull. 2019;67(3):258–64. Zhang Q, Wang J, Liu H, Ma W, Zhou S, Zhou J. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020 Aug;45:1434. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013 Apr;57(4):1756–62. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014 May 5;18(3):R90. Baron J, Cai S, Klein N, Cunha BA. Once daily high dose tigecycline is optimal: tigecycline PK/PD parameters predict clinical effectiveness. J Clin Med. 2018 Mar 9;7(3):49. Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine. 2020 Mar;99(10):e19466. Xie J, Roberts JA, Alobaid AS, Roger C, Wang Y, Yang Q, et al. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Antimicrob Agents Chemother. 2017 Aug;61(8):e00345–17. Treml B, Rajsic S, Hell T, Fries D, Bachler M. Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis. J Clin Med. 2021 Oct;13(20):10. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99–110. Gounden V, Vashisht R, Jialal I. Hypoalbuminemia. In: StatPearls. Treasure island, FL: StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022. Shi X, Zuo C, Yu L, Lao D, Li X, Xu Q, et al. Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM. Front Pharmacol. 2021;12:761167. Waack U, Warnock M, Yee A, Huttinger Z, Smith S, Kumar A, et al. CpaA is a glycan-specific adamalysin-like protease secreted by acinetobacter baumannii that inactivates coagulation factor XII. mBio. 2018 Dec 18;9(6):e01606–18. Bachler M, Niederwanger C, Hell T, Höfer J, Gerstmeyr D, Schenk B, et al. Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients. J Thromb Thrombolysis. 2019 Oct;48(3):466–74. Wong RS, Cheng G, Chan NP, Wong WS, Ng MH. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol. 2006 Jan;81(1):76. Vasse M, Paysant I, Soria J, Mirshahi SS, Vannier JP, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 1996 Jun;93(4):955–61. Saliba R, Paasch L, El Solh A. Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol. 2009;31(4):583–8. Rein-Smith CM, Anderson NW, Farrell DH. Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6. Thromb Res. 2013 Jan;131(1):89–93. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol. 2007 Feb;56(Pt 2):165–71. Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019 Jul;6(3):223–32. Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: January 29, 2022
Accepted: May 30, 2022
Published online: July 12, 2022

Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 5

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif